RGFields for Tuberculosis
Tuberculosis
Pre-clinicalActive
Key Facts
About Anapole Technologies
Anapole Technologies is a private, pre-revenue medical device and drug delivery company commercializing a novel, non-invasive therapeutic platform based on Resonance Generating Fields (RGFields). The technology has shown clinical effectiveness against HIV and pre-clinical success in tuberculosis and certain cancers, positioning it as a potential paradigm shift in treatment modalities. Led by an experienced team with strong financial and military backgrounds, the company is seeking strategic partners to bring its cost-effective, scalable system to market. Its value proposition centers on high ROI for providers and broader patient access due to lower treatment costs and backward-compatible hardware upgrades.
View full company profileTherapeutic Areas
Other Tuberculosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine TB Vaccine | Vaxine | Preclinical |
| Isoniazid Oral Solution, USP | CMP Pharma | Approved |
| Tuberculosis Program | Fimbrion Therapeutics | Preclinical |
| Undisclosed Program | Crestone | Preclinical |
| Tuberculosis Diagnostic | GenEndeavor | Research/Exploratory |
| TB Screening LFA | DiagMetrics | Development |
| Tuberculosis Nanobody | VicuTec Biologicals | Pre-clinical |
| Not specified on provided pages | Cadila Pharmaceuticals | Commercial (World's First Claim) |
| TB Diagnostic & Drug Discovery | Avesthagen | Research/Discovery |
| ALF Platform | Senzo | Pre-clinical |
| Satiro Tablets | KYORIN Pharmaceutical | Registration |